SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 135 filers reported holding SYNDAX PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 0.21 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,781,500 | -91.4% | 70,000 | -91.9% | 1.63% | -36.8% |
| Q3 2022 | $20,648,000 | +16.2% | 859,240 | -6.9% | 2.58% | +44.6% |
| Q2 2022 | $17,766,000 | -13.4% | 923,400 | -21.8% | 1.78% | +30.4% |
| Q1 2022 | $20,517,000 | -19.0% | 1,180,500 | +2.0% | 1.37% | -0.7% |
| Q4 2021 | $25,339,000 | +9.2% | 1,157,560 | -4.7% | 1.38% | +37.6% |
| Q3 2021 | $23,212,000 | -22.8% | 1,214,670 | -30.6% | 1.00% | -16.6% |
| Q2 2021 | $30,071,000 | -1.9% | 1,751,342 | +27.7% | 1.20% | +10.8% |
| Q1 2021 | $30,666,000 | +28.8% | 1,371,480 | +28.1% | 1.08% | +18.2% |
| Q4 2020 | $23,809,000 | +4912.4% | 1,070,550 | +3224.7% | 0.92% | +4731.6% |
| Q3 2020 | $475,000 | – | 32,200 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,025,000 | $21,648,000 | 10.42% |
| Foresite Capital Management IV, LLC | 875,000 | $18,480,000 | 9.59% |
| Kynam Capital Management, LP | 3,205,986 | $67,710,424 | 8.74% |
| Frazier Life Sciences Management, L.P. | 3,708,838 | $78,330,659 | 5.67% |
| ACUTA CAPITAL PARTNERS, LLC | 330,000 | $6,969,600 | 5.13% |
| Paradigm Biocapital Advisors LP | 2,274,512 | $48,037,693 | 4.55% |
| Eversept Partners, LP | 2,209,057 | $46,655,284 | 3.25% |
| DAFNA Capital Management LLC | 447,073 | $9,442,182 | 2.83% |
| COMMODORE CAPITAL LP | 853,884 | $18,034,030 | 2.75% |
| Avidity Partners Management LP | 3,865,300 | $81,635,136 | 2.71% |